Developer docs
API playgroundTry for free, no card

Search company profiles

Inceptive

Full company profile

uuid0000d4w

Namestring
Inceptive
Legal namestring
Inceptive Nucleics, Inc.
Websiteurl
inceptive.life
Company typeenum
Private
Founded yearint
2021
Descriptiontext

Inceptive (legal entity: Inceptive Nucleics, Inc.) is a private AI biotech founded in 2021 and headquartered in Palo Alto, California, with additional offices in Berlin and Zurich. The company builds end-to-end foundation models trained on heterogeneous, multi-scale biological data spanning sequence, function, and structure, with a focus on designing sequence-based therapeutics including mRNA, siRNA, antisense oligonucleotides (ASOs), and peptides. A defining architectural element is the tight loop between in-silico model training and an in-house wet laboratory that validates designs in vitro and in vivo at high frequency, shortening the path from computational design to drug candidate. Proprietary algorithms are engineered to extrapolate beyond the best molecules in the training data, iteratively proposing designs superior to anything previously observed.

The company serves large pharmaceutical and biotechnology companies through a direct strategic-partnership model rather than a self-serve or SaaS offering. Partnerships involve customizing foundation models against partner-specific data, co-designing novel therapeutic candidates, and transferring knowledge so that partners can advance candidates to the clinic. Revenue derives from upfront licensing payments and milestone payments tied to preclinical, regulatory, and commercial achievements. The flagship disclosed commercial deal is a three-year collaboration with Alnylam Pharmaceuticals announced in June 2026, valued at up to $2 billion with a $30 million upfront payment in cash and equity, targeting RNAi therapeutic discovery.

Inceptive is backed by Andreessen Horowitz (a16z), NVIDIA, S32, and Obvious Ventures, and has raised approximately $120 million across two disclosed funding rounds (a Series A of roughly $20 million in 2022 and a $100 million round in September 2023 co-led by a16z and NVIDIA). Leadership is anchored by CEO Jakob Uszkoreit, co-inventor of the Transformer architecture and former Google Brain researcher. As of the latest data, the company has 11–50 employees (approximately 28 visible in team photos), is privately held with no public ticker, and has not disclosed revenue figures.

Short descriptiontext

Inceptive (Inceptive Nucleics, Inc.) builds AI foundation models trained on heterogeneous biological data and validated by an in-house wet lab to design sequence-based therapeutics — mRNA, siRNA, ASOs, and peptides — for large pharmaceutical and biotechnology partners under licensing and milestone-based collaboration agreements.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersPalo Alto, United States
HQ citystring
Palo Alto
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices4 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
AI drug discovery, foundation models biology, RNA therapeutics design, molecular design platform, biotech AI partnerships
Industry5 codes
PRIMARYHLAAADAG
RNA Therapeutics Platforms & Design (sequence design, target ID/validation, AI/bioinformatics)
Healthcare & Life Sciences/Biotechnology & Biologics/RNA Therapeutics (mRNA, siRNA, ASO)
SECONDARYHLAAAIAE
AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAGAJAO
AI/ML Platforms for Drug Discovery & Experiment Optimization
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
SECONDARYHLAAADAE
RNA Chemistry & Oligonucleotide Engineering (backbones, modifications, stereochemistry)
Healthcare & Life Sciences/Biotechnology & Biologics/RNA Therapeutics (mRNA, siRNA, ASO)
SECONDARYHLAAADAC
Antisense Oligonucleotides (ASO) Therapeutics (splice modulation/knockdown)
Healthcare & Life Sciences/Biotechnology & Biologics/RNA Therapeutics (mRNA, siRNA, ASO)
NAICS code2 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Scientific Research and Development Services5417
SIC code3 codes
  • Services-Commercial Physical & Biological Research8731
  • Services-Medical Laboratories8071
  • Biological Products, (No Disgnostic Substances)2836
Product category
AI-Driven Biopharmaceutical R&D
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model2 records
1Strategic Partnership Licensing
TypeLicensing Royalties
Description

Licensing AI foundation models to pharmaceutical partners with upfront payments, followed by milestone payments tied to preclinical, regulatory, and commercial achievements. Total deal value can reach up to $2 billion for flagship partnerships.

businesswire.com
2Co-development Agreements
TypeProfessional Services
Description

Working with partners to co-design novel medicines and transfer knowledge, empowering partners to take candidates to clinic. Revenue derived from collaborative research payments and development milestones.

businesswire.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Operations, Infrastructure, Marketing or Sales
GTM typeB2B
B2B
Offering typeSoftware
Software
Core offering1 text field

Inceptive designs RNA-based therapeutics using AI foundation models trained on heterogeneous biological data (sequence, function, and structure), specializing in mRNA, siRNA, ASOs, and peptides. The company pairs these foundation models with an in-house wet lab that validates designs in vitro and in vivo, enabling rapid iterative design-to-candidate cycles. It monetizes this capability by partnering with pharmaceutical and biotechnology companies to customize foundation models and co-design novel medicines.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 2 values shown
  • Reduced discovery timelines through AI-powered siRNA design
+1 more record
Product overview1 text field

Inceptive offers a unified AI-powered drug discovery platform consisting of foundation models trained on biological data and an in-house wet lab for validation. The platform specializes in sequence-based medicines (mRNA, siRNA, ASOs, peptides) and combines deep learning models with experimental validation to design novel therapeutic candidates. The company also provides partnership services to customize foundation models for specific drug discovery programs.

Product and service2 records
1AI Foundation Models for Drug Discovery
CategoryAI Drug Discovery Platform
Description

End-to-end foundation models that learn to design molecules directly from diverse observations of life, specializing in sequence-based medicines (mRNA, siRNA, ASOs, peptides). Models train on public datasets, in-house experimental data, and partner data, and are engineered to extrapolate beyond the best molecules in training data. Licensed to pharmaceutical and biotechnology partners for use in their discovery programs.

2Custom Foundation Model Partnerships
CategoryAI Customization Services
Description

Custom foundation models built in collaboration with pharmaceutical and biotechnology partners for their specific discovery programs. Includes joint co-design of novel medicines, tuning of models on partner data, and knowledge transfer so partners can advance candidates to the clinic. Delivered via strategic collaborations with upfront payments and milestone-based compensation tied to preclinical, regulatory, and commercial outcomes.

Scale indicator4 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
Strategic tierFlagshipTypeStrategic or Co-development PartnerAnnounced on2026-06-03
Description

Three-year strategic collaboration worth up to $2 billion to accelerate RNAi therapeutics discovery. Inceptive provides AI foundation models; Alnylam contributes 20+ years of proprietary siRNA data and RNAi platform expertise. Deal includes $30 million upfront with additional preclinical, regulatory, and commercial milestone payments. Aims to enhance siRNA design and support Alnylam's 2030 pipeline expansion strategy.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

AI foundation-model platform for protein and sequence-based therapeutic design. Closely analogous in framing ('generative biology' foundation models) and modality span to Inceptive.

TypeDirect peer
Description

AI-driven drug discovery platform combining generative chemistry, target identification, and preclinical development. Comparable in offering end-to-end AI drug discovery with strategic pharma partnerships.

TypeEmerging player
Description

Frontier AI research company building large models for biology. Closely parallels Inceptive's foundation-model framing of biology, though more research-stage and modality-agnostic.

TypeEmerging player
Description

AI platform for protein design and engineering with a wet-lab loop. Comparable in combining generative AI with experimental validation, though more focused on proteins rather than RNA.

5Isomorphic Labs
TypeDirect peer
Description

Alphabet/DeepMind-founded AI drug discovery company building foundation models for therapeutic design. Most direct competitor in the AI foundation-models-for-biology category, with overlapping modality ambitions and partner-based GTM.

TypeBroad incumbent
Description

Parent organization of Isomorphic Labs and developer of AlphaFold. Relevant as the broad incumbent whose biology AI efforts (and spinoff) most directly compete with Inceptive's foundation-model approach.

TypeDirect peer
Description

AI small-molecule discovery company with pharma partnerships. Comparable as an AI-first drug discovery platform with enterprise partnership GTM, though more structure-based and small-molecule focused.

TypeOthers
Description

Flagship strategic partner and dominant siRNA therapeutics company. Listed as 'others' because it is currently a customer/partner rather than a competitor, but it operates in the same RNA therapeutics category and represents the most validated end-market.

TypeEmerging player
Description

AI foundation models for protein engineering and sequence design, founded by AI researchers. Comparable in technical thesis (deep learning from life / biology foundation models) though initially protein-focused.

TypeBroad incumbent
Description

Publicly listed AI drug discovery company combining high-throughput wet-lab experimentation with ML. Compares as a larger, established player in the AI-bio space with internal pipeline plus partnerships.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers1 record

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability4 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles1 record

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds2 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors5 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Inceptive

AI-Driven Biopharmaceutical R&Dinceptive.life

Inceptive (Inceptive Nucleics, Inc.) builds AI foundation models trained on heterogeneous biological data and validated by an in-house wet lab to design sequence-based therapeutics — mRNA, siRNA, ASOs, and peptides — for large pharmaceutical and biotechnology partners under licensing and milestone-based collaboration agreements.

What Inceptive does

Inceptive (legal entity: Inceptive Nucleics, Inc.) is a private AI biotech founded in 2021 and headquartered in Palo Alto, California, with additional offices in Berlin and Zurich. The company builds end-to-end foundation models trained on heterogeneous, multi-scale biological data spanning sequence, function, and structure, with a focus on designing sequence-based therapeutics including mRNA, siRNA, antisense oligonucleotides (ASOs), and peptides. A defining architectural element is the tight loop between in-silico model training and an in-house wet laboratory that validates designs in vitro and in vivo at high frequency, shortening the path from computational design to drug candidate. Proprietary algorithms are engineered to extrapolate beyond the best molecules in the training data, iteratively proposing designs superior to anything previously observed.

The company serves large pharmaceutical and biotechnology companies through a direct strategic-partnership model rather than a self-serve or SaaS offering. Partnerships involve customizing foundation models against partner-specific data, co-designing novel therapeutic candidates, and transferring knowledge so that partners can advance candidates to the clinic. Revenue derives from upfront licensing payments and milestone payments tied to preclinical, regulatory, and commercial achievements. The flagship disclosed commercial deal is a three-year collaboration with Alnylam Pharmaceuticals announced in June 2026, valued at up to $2 billion with a $30 million upfront payment in cash and equity, targeting RNAi therapeutic discovery.

Inceptive is backed by Andreessen Horowitz (a16z), NVIDIA, S32, and Obvious Ventures, and has raised approximately $120 million across two disclosed funding rounds (a Series A of roughly $20 million in 2022 and a $100 million round in September 2023 co-led by a16z and NVIDIA). Leadership is anchored by CEO Jakob Uszkoreit, co-inventor of the Transformer architecture and former Google Brain researcher. As of the latest data, the company has 11–50 employees (approximately 28 visible in team photos), is privately held with no public ticker, and has not disclosed revenue figures.

Inceptive firmographics

Firmographics
Name
Inceptive
Legal name
Inceptive Nucleics, Inc.
Website
https://inceptive.life
Company type
Private
Founded year
2021
Operating status
Operating
Headcount range
51–100 employees
Short description
Inceptive (Inceptive Nucleics, Inc.) builds AI foundation models trained on heterogeneous biological data and validated by an in-house wet lab to design sequence-based therapeutics — mRNA, siRNA, ASOs, and peptides — for large pharmaceutical and biotechnology partners under licensing and milestone-based collaboration agreements.
Ownership category
akta.pro rank

Inceptive industry classification

Industry
Product category
AI-Driven Biopharmaceutical R&D
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)
SIC
Services-Commercial Physical & Biological Research (8731), Services-Medical Laboratories (8071), Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAAADAG
RNA Therapeutics Platforms & Design (sequence design, target ID/validation, AI/bioinformatics)
Healthcare & Life Sciences/Biotechnology & Biologics/RNA Therapeutics (mRNA, siRNA, ASO)
SECONDARYHLAAAIAE
AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAGAJAO
AI/ML Platforms for Drug Discovery & Experiment Optimization
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
SECONDARYHLAAADAE
RNA Chemistry & Oligonucleotide Engineering (backbones, modifications, stereochemistry)
Healthcare & Life Sciences/Biotechnology & Biologics/RNA Therapeutics (mRNA, siRNA, ASO)
SECONDARYHLAAADAC
Antisense Oligonucleotides (ASO) Therapeutics (splice modulation/knockdown)
Healthcare & Life Sciences/Biotechnology & Biologics/RNA Therapeutics (mRNA, siRNA, ASO)

Keywords

  • AI drug discovery
  • Foundation models biology
  • RNA therapeutics design
  • Molecular design platform
  • Biotech AI partnerships

Where Inceptive is headquartered

Location

Headquarters

HQ city
Palo Alto
HQ country
United States
HQ region
North America

Offices4 records

Markets served

Inceptive business model

Business model
GTM type
B2B
Offering type
Software
Cost components
Personnel, Technology or R&D, Operations, Infrastructure, Marketing or Sales

Revenue model

  1. Strategic Partnership Licensing: Licensing AI foundation models to pharmaceutical partners with upfront payments, followed by milestone payments tied to preclinical, regulatory, and commercial achievements. Total deal value can reach up to $2 billion for flagship partnerships.
  2. Co-development Agreements: Working with partners to co-design novel medicines and transfer knowledge, empowering partners to take candidates to clinic. Revenue derived from collaborative research payments and development milestones.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Inceptive product offering

Product offering

Core offering

Inceptive designs RNA-based therapeutics using AI foundation models trained on heterogeneous biological data (sequence, function, and structure), specializing in mRNA, siRNA, ASOs, and peptides. The company pairs these foundation models with an in-house wet lab that validates designs in vitro and in vivo, enabling rapid iterative design-to-candidate cycles. It monetizes this capability by partnering with pharmaceutical and biotechnology companies to customize foundation models and co-design novel medicines.

Product overview

Inceptive offers a unified AI-powered drug discovery platform consisting of foundation models trained on biological data and an in-house wet lab for validation. The platform specializes in sequence-based medicines (mRNA, siRNA, ASOs, peptides) and combines deep learning models with experimental validation to design novel therapeutic candidates. The company also provides partnership services to customize foundation models for specific drug discovery programs.

Differentiator

Problem solved

Functional benefit

Products and services

  • AI Foundation Models for Drug Discovery End-to-end foundation models that learn to design molecules directly from diverse observations of life, specializing in sequence-based medicines (mRNA, siRNA, ASOs, peptides). Models train on public datasets, in-house experimental data, and partner data, and are engineered to extrapolate beyond the best molecules in training data. Licensed to pharmaceutical and biotechnology partners for use in their discovery programs.
  • Custom Foundation Model Partnerships Custom foundation models built in collaboration with pharmaceutical and biotechnology partners for their specific discovery programs. Includes joint co-design of novel medicines, tuning of models on partner data, and knowledge transfer so partners can advance candidates to the clinic. Delivered via strategic collaborations with upfront payments and milestone-based compensation tied to preclinical, regulatory, and commercial outcomes.

Quantifiable outcome

  • Reduced discovery timelines through AI-powered siRNA design
  • +1 more outcomes

Companies that use Inceptive

Customer profile

Named customers1 record

Segments2 records

Ideal customer profiles2 records

Inceptive technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability4 records

Feature4 records

Inceptive partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • Alnylam PharmaceuticalsflagshipStrategic or Co-development Partner · 3 June 2026Three-year strategic collaboration worth up to $2 billion to accelerate RNAi therapeutics discovery. Inceptive provides AI foundation models; Alnylam contributes 20+ years of proprietary siRNA data and RNAi platform expertise. Deal includes $30 million upfront with additional preclinical, regulatory, and commercial milestone payments. Aims to enhance siRNA design and support Alnylam's 2030 pipeline expansion strategy.

Scale indicators4 records

Recent moves6 records

Expansion highlights5 records

Inceptive competitors and assessment

Company assessment

Direct peers

  • Generate:Biomedicines: AI foundation-model platform for protein and sequence-based therapeutic design. Closely analogous in framing ('generative biology' foundation models) and modality span to Inceptive.
  • Insilico Medicine: AI-driven drug discovery platform combining generative chemistry, target identification, and preclinical development. Comparable in offering end-to-end AI drug discovery with strategic pharma partnerships.
  • Isomorphic Labs: Alphabet/DeepMind-founded AI drug discovery company building foundation models for therapeutic design. Most direct competitor in the AI foundation-models-for-biology category, with overlapping modality ambitions and partner-based GTM.
  • Atomwise: AI small-molecule discovery company with pharma partnerships. Comparable as an AI-first drug discovery platform with enterprise partnership GTM, though more structure-based and small-molecule focused.

Emerging players

  • EvolutionaryScale: Frontier AI research company building large models for biology. Closely parallels Inceptive's foundation-model framing of biology, though more research-stage and modality-agnostic.
  • Cradle Bio: AI platform for protein design and engineering with a wet-lab loop. Comparable in combining generative AI with experimental validation, though more focused on proteins rather than RNA.
  • Profluent Bio: AI foundation models for protein engineering and sequence design, founded by AI researchers. Comparable in technical thesis (deep learning from life / biology foundation models) though initially protein-focused.

Broad incumbents

  • DeepMind (Google): Parent organization of Isomorphic Labs and developer of AlphaFold. Relevant as the broad incumbent whose biology AI efforts (and spinoff) most directly compete with Inceptive's foundation-model approach.
  • Recursion Pharmaceuticals: Publicly listed AI drug discovery company combining high-throughput wet-lab experimentation with ML. Compares as a larger, established player in the AI-bio space with internal pipeline plus partnerships.

Others

  • Alnylam Pharmaceuticals: Flagship strategic partner and dominant siRNA therapeutics company. Listed as 'others' because it is currently a customer/partner rather than a competitor, but it operates in the same RNA therapeutics category and represents the most validated end-market.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Inceptive social profiles

Digital presence

Inceptive financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Inceptive leadership team

Management profile

Number of profiles

Profiles1 record

Inceptive funding detail

Funding detail

Funding overview

Funding rounds2 records

Investors5 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Inceptive M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Inceptive

What does Inceptive do?

Inceptive designs RNA-based therapeutics using AI foundation models trained on heterogeneous biological data (sequence, function, and structure), specializing in mRNA, siRNA, ASOs, and peptides. The company pairs these foundation models with an in-house wet lab that validates designs in vitro and in vivo, enabling rapid iterative design-to-candidate cycles. It monetizes this capability by partnering with pharmaceutical and biotechnology companies to customize foundation models and co-design novel medicines.

Is Inceptive a public or private company?

Inceptive is a private company. It is classified as venture growth investor backed and is currently operating.

When was Inceptive founded?

Inceptive was founded in 2021. It employs 51 to 100 people.

Where is Inceptive based?

Inceptive is headquartered in Palo Alto, United States, in the North America region.

How does Inceptive make money?

Two revenue lines are on record. Strategic Partnership Licensing is the primary driver. The others are co-development Agreements.

Who are Inceptive's main competitors?

Direct peers on record are Generate:Biomedicines, Insilico Medicine, Isomorphic Labs and Atomwise. Emerging players are EvolutionaryScale, Cradle Bio and Profluent Bio. Broad incumbents are DeepMind (Google) and Recursion Pharmaceuticals. Alnylam Pharmaceuticals is listed as an others.

Does Inceptive have an API?

No public API is recorded for Inceptive.

What industry is Inceptive in?

Inceptive's product category is AI-Driven Biopharmaceutical R&D. Its primary akta.pro industry code is HLAAADAG, RNA Therapeutics Platforms & Design (sequence design, target ID/validation, AI/bioinformatics), with a secondary code of HLAAAIAE, AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening). Its NAICS code is 541714 and its SIC code is 8731.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
The Motley FoolWall Street Thinks This Biotech Stock Can Soar 45%. Here's Why Analysts Are Right.Alnylam Pharmaceuticals shares fell 24% year-to-date, but analysts see upside, with 14 of 29 rating it a buy and an average price target of $436. Q1 product revenue surged 121% to $1.04 billion, driven by Amvuttra, and the company is transitioning to a profitable, self-sustaining business.YahooAlnylam Pharmaceuticals (ALNY), Inceptive Form $2B Partnership to Advance RNAi Drug DiscoveryAlnylam Pharmaceuticals and Inceptive Nucleics announced a collaboration on June 3 valued at up to $2 billion to accelerate RNAi drug discovery, combining Alnylam's RNAi platform and proprietary data with Inceptive's AI foundation models. Under the agreement, Inceptive will receive $30 million in upfront consideration with potential milestone payments tied to preclinical, regulatory, and commercial achievements. The partnership aims to shorten discovery timelines and support Alnylam's 'Alnylam 2030' pipeline expansion strategy by leveraging generative AI for oligonucleotide design.Phirda20亿美元!AI制药再迎重磅合作Alnylam announced a $2 billion strategic partnership with AI+mRNA startup Inceptive, with a $30 million upfront payment. Inceptive, founded by Jakob Uszkoreit, applies Transformer-based AI to RNA drug design and has raised $100 million in funding.Longevity.TechnologyAlnylam, Inceptive partner in $2b AI deal to design next-gen RNA medicinesAlnylam and Inceptive announced a strategic collaboration to integrate Inceptive's generative AI models with Alnylam's RNAi R&D, valued at up to $2 billion with $30 million upfront. The deal includes additional milestone payments and gives Alnylam access to Inceptive's talent, including CEO Jakob Uszkoreit.GeneOnline NewsAI Industry Leaders Urge Congress to Regulate Genomic Data Amid New Biotech PartnershipsAI industry leaders are urging Congress to implement federal safeguards for DNA data amid growing security concerns as AI tools become more capable of processing genetic information. This push follows a strategic partnership between Inceptive Nucleics and Alnylam Pharmaceuticals to leverage AI for accelerating RNA-based therapeutics development. Separately, researchers are re-evaluating data from Grail's recent clinical trial, which did not meet its primary endpoints but provides insights into multi-cancer early detection technologies.BioPharma DiveAlnylam, Inceptive ink AI deal potentially worth $2BAlnylam Pharmaceuticals has partnered with biotechnology company Inceptive Nucleics to access AI tools for accelerating RNA-based therapy discovery, with $30 million paid upfront and potential milestone payments reaching up to $2 billion. The partnership supports Alnylam's "Alnylam 2030" strategy aimed at ambitious pipeline expansion through improved molecule prioritization. The deal reflects a broader pharmaceutical industry trend of embracing AI for drug development, though questions remain about the long-term effectiveness of AI in this field.Simply Wall StAI Collaboration Puts Alnylam’s RNAi Pipeline Productivity In FocusAlnylam Pharmaceuticals has announced a collaboration with AI firm Inceptive Nucleics to apply generative AI models to RNAi drug design, aiming to improve research productivity and speed for new therapeutics. The deal is valued at up to US$2.0 billion, with only US$30 million committed upfront through cash and equity, while the remainder is tied to preclinical, regulatory, and commercial milestones. This partnership is positioned as a key step toward advancing Alnylam's Alnylam 2030 strategy and may help the company expand its pipeline beyond its transthyretin (TTR) franchise.The Pharma LetterAlnylam signs $2 billion AI pact with InceptiveAlnylam Pharmaceuticals signed a strategic AI collaboration with Inceptive Nucleics to accelerate RNA interference therapy discovery. The deal is valued at up to $2 billion, with $30 million upfront and potential milestones. The partnership supports Alnylam's Alnylam 2030 strategy.BioSpaceAlnylam and Inceptive Form Strategic AI Collaboration to Accelerate the Discovery of RNAi TherapeuticsAlnylam and Inceptive announced a strategic collaboration to accelerate RNAi therapeutics discovery, valued at up to $2B with $30M upfront. The partnership combines Alnylam's RNAi platform and 20+ years of data with Inceptive's foundation models. Inceptive is eligible for additional milestone payments.MarketScreenerExceptional is no longer enoughUS tech stocks fell after Broadcom, CrowdStrike, and Netskope reported disappointing results, with Broadcom dropping 14% in after-hours trading. The market's skepticism about AI bubble risk persists, and traders expect a hawkish Fed tone amid inflation concerns. The day opens cautiously ahead of US employment data.